Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell
10 Stocks Moving In Tuesday's Pre-Market Session
Regeneron Disappoints, The Stock Sells Off: Analysis Of Its Growth Potential (Seeking Alpha)
Related AGN
BoA Adds Pfizer To US 1 List; It 'Won't Keep You Up At Night'
How To Invest In An Aging World With The 'Live Long & Prosper' ETF
Celgene Can Earn $7.50 Next Year - Cramer's Lightning Round (2/8/16) (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Feb 2016BarclaysMaintainsEqual-weight
Feb 2016Brean CapitalMaintainsBuy
Feb 2016UBSMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters